Dr. Péter Ferdinandy, MD, PhD, MBA
Vice-Rector
Date and place of birth
1966, Békéscsaba, Hungary
Current positions
- since 2018: Vice-Rector for Science and Innovations, Semmelweis University
- since 2011: Professor & Director, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University
- since 2001: Founder and CEO of Pharmahungary Group, Szeged, Hungary (spin-off companies)
Education and scientific degrees
- 2004: DSc in medical sciences, Hungarian Academy of Sciences
- 2000-2004: MBA (Masters of Business Administration, Finance and Quality management), Budapest Technical University, Hungary
- 1999: Designation as registered Clinical-Pharmacologist
- 1997-1999: Postdoctoral training, Dept Pharmacology, University of Alberta, Edmonton, Canada1995 December
- 1991-1995: PhD training, Departments of Physiology and Biochemistry, University of Szeged, Hungary
- 1991: MD diploma (score: excellent, “summa cum laude”)
- 1985-1991: University of Szeged, Hungary
Teaching experience
- since 2004: Lecturer in Pharmacology, Semmelweis University, Budapest
- since 1993: Lecturer in Biochemistry, University of Szeged, Hungary
- 1998-1999: Lecturer in Pharmacology, University of Alberta, Edmonton, Canada
- 1991-1994: Lecturer in Physiology, University of Szeged, Hungary
Scholarships, fellowships
- 1989-1991: Scholarship of Hungarian Republic
- 1997-1999: Postdoc Fellow, MRC Canada, University of Alberta, Canada
- 2001-2005: Szechenyi professorship, Hungarian Academy of Sciences
- 2013-2014: Szentagothai professorship, National Excellence Program
Major awards
First prize, Young Investigator Award 1999, International Society for Heart Research
Major leadership positions at international scientific organizations
- 2012-2014: President, International Society for Heart Research, European Section
- 2014-2016: Chairman, Working Group Cell Biology of the Heart, European Cardiology Society
- 2019-2023: President, Hungarian Society of Experimental and Clinical Pharmacology
Editorial board memberships
- Editor-in-Chief: British Journal of Pharmacology, since 2023
- Br J Pharmacol (Reviews Editor, Guest Editor, impact factor 4.9)
- J Mol Cell Cardiol (Editor, impact factor 5.1)
- Basic Res Cardiol (Editor, impact factor 5.9)
- J Pharmacol Tox Methods (Editor, impact factor 2.2)
- Vascular Pharmacology (Editor, impact factor 3.7)
Languages
- Native language: Hungarian
- English (fluent)
- German (basic understanding)
Scientometric data
- Number of papers in international peer-reviewed journals: over 350 (source: PubMed)
- Cumulative impact factor of full papers: over 1600
- Total number of citations: over 26,000, independent: 14,000 (Hungarian Science Bibliography), publications cited over 100 times: 64 (source: Google Scholar)
- Hirsch index: 69 (source: Google Scholar)
- Patent families: 6, software developments: 3 on the market
- Highly Cited Researcher in the field of Cross-Field: 2020, 2021, 2022, 2023, 2024
- Highly Cited Researcher in the field of Pharmacology and Toxicology: 2014, 2017